A detailed history of Blume Capital Management, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Blume Capital Management, Inc. holds 2,204 shares of BMY stock, worth $127,126. This represents 0.03% of its overall portfolio holdings.

Number of Shares
2,204
Previous 2,475 10.95%
Holding current value
$127,126
Previous $102,000 11.76%
% of portfolio
0.03%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$39.66 - $51.75 $10,747 - $14,024
-271 Reduced 10.95%
2,204 $114,000
Q2 2023

May 01, 2024

BUY
$63.71 - $70.74 $17,265 - $19,170
271 Added 12.3%
2,475 $158,000
Q2 2023

Aug 10, 2023

BUY
$63.71 - $70.74 $17,265 - $19,170
271 Added 12.3%
2,475 $158,000
Q1 2023

May 01, 2024

SELL
$65.71 - $74.53 $17,807 - $20,197
-271 Reduced 10.95%
2,204 $152,000
Q4 2022

Feb 07, 2023

SELL
$68.48 - $81.09 $27,392 - $32,436
-400 Reduced 15.36%
2,204 $158,000
Q2 2022

Aug 11, 2022

SELL
$72.62 - $79.98 $14,524 - $15,996
-200 Reduced 7.13%
2,604 $201,000
Q4 2020

Feb 09, 2021

SELL
$57.74 - $65.43 $11,548 - $13,086
-200 Reduced 6.66%
2,804 $174,000
Q4 2019

Feb 05, 2020

BUY
$49.21 - $64.19 $49,210 - $64,190
1,000 Added 49.9%
3,004 $192,000
Q3 2019

Nov 12, 2019

SELL
$42.77 - $50.71 $15,012 - $17,799
-351 Reduced 14.9%
2,004 $101,000
Q4 2018

Feb 05, 2019

BUY
$48.76 - $63.23 $12,190 - $15,807
250 Added 11.88%
2,355 $122,000
Q3 2018

Nov 02, 2018

BUY
$55.19 - $62.25 $13,797 - $15,562
250 Added 13.48%
2,105 $131,000
Q1 2018

May 04, 2018

SELL
$59.92 - $68.98 $2,996 - $3,449
-50 Reduced 2.62%
1,855 $117,000
Q4 2017

Feb 12, 2018

SELL
$59.94 - $65.35 $5,994 - $6,534
-100 Reduced 4.99%
1,905 $117,000
Q3 2017

Nov 13, 2017

BUY
$55.23 - $63.74 $110,736 - $127,798
2,005
2,005 $128,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Blume Capital Management, Inc. Portfolio

Follow Blume Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blume Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Blume Capital Management, Inc. with notifications on news.